European Commission Grants Orphan Medicinal Product Designation To Astria Therapeutics' Navenibart For Treatment Of Hereditary Angioedema; Phase 1b/2 Trial Shows 90-96% Reduction In Monthly Attack Rates With Favorable Safety Profile
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted Orphan Medicinal Product Designation to Astria Therapeutics' drug, Navenibart, for the treatment of hereditary angioedema. The Phase 1b/2 trial demonstrated a 90-96% reduction in monthly attack rates with a favorable safety profile.
October 16, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astria Therapeutics' Navenibart has been granted Orphan Medicinal Product Designation by the European Commission for hereditary angioedema, with trial results showing significant reduction in attack rates.
The Orphan Medicinal Product Designation is a significant regulatory milestone that can lead to market exclusivity and other benefits in the EU. The positive trial results further enhance the drug's potential, likely boosting investor confidence and positively impacting ATXS's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100